US Markets

Spanish pharma Grifols buys plasma assets from Green Cross for $460 mln

Spanish pharmaceutical company Grifols said on Monday it agreed to buy plasma assets in North America from South Korea's Green Cross for $460 million.

MADRID, July 20 (Reuters) - Spanish pharmaceutical company Grifols said on Monday it agreed to buy plasma assets in North America from South Korea's Green Cross for $460 million.

Grifols will buy a plasma fractionation plant in Canada and two purification facilities and 11 plasma collection centres in the United States, the company said in a statement.

The Barcelona-based firm will need no new financing to carry out the acquisition, it said.

Grifols is one of the world's top producers of treatments based on human plasma.

(Reporting by Inti Landauro; editing by Jason Neely)

((Inti.Landauro@thomsonreuters.com;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos

    Reuters

    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

    Learn More